Clinical Trials Logo

Filter by:
NCT ID: NCT06178146 Recruiting - IrAE Clinical Trials

Thymosin Alpha-1 for irAE Secondary to ICIs

Start date: September 1, 2023
Phase: Phase 4
Study type: Interventional

Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are severely compromised or ineffective. Therefore, this study is attempted to explore whether Tα-1 could be used as a therapeutic option for the treatment of immune-related adverse events (irAEs).

NCT ID: NCT06178003 Recruiting - Clinical trials for Salmonella Bacteremia

the Safety and Efficacy of Intravitreal Injection of Tpdelansbsalbac in Malignant Effusions.

Start date: February 11, 2024
Phase: N/A
Study type: Interventional

This is a Phase I/II, open, first-in-human (FIH) study of Transebacillus in Patients with malignant pleural and abdominal effusions. It consists of Phase Ia to determine the Maximum tolerated dose (MTD) or Recommended Phase 2 dose (RP2D) of Transebacillus, and Phase Ib/II to explore and confirm the efficacy, safety and Tolerability.

NCT ID: NCT06177925 Recruiting - Neoplasms Clinical Trials

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Start date: December 10, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin/Cisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.

NCT ID: NCT06177561 Recruiting - Leukemia Clinical Trials

Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT

Start date: November 9, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to prospectively explore the effectiveness and safety of LPE in clearing DSA, and to investigate the clinical efficacy of a combination therapy with LPE in patients undergoing genetic hematopoietic stem cell transplantation.

NCT ID: NCT06177548 Recruiting - Aortic Dissection Clinical Trials

Safety and Efficacy of the Minimally Invasive Bentall Procedure Via a Small Right Intercostal Incision in Patients With Aortic Root Lesions

Mini-Bentall
Start date: December 11, 2023
Phase:
Study type: Observational

This study intends to include patients who had aortic root lesions and were treated with Bentall surgery from January 2019 to July 2023 in the First Affiliated Hospital of Xi'an Jiaotong University. The patients will be divided into the minimally invasive group and control group according to the surgical methods: the former underwent minimally invasive Bentall surgery through a small right intercostal incision; the latter underwent traditional Bentall surgery through a median sternal incision. By comparing the clinical data of patients in two groups, we will investigate the effect and safety of minimally invasive Bentall surgery.

NCT ID: NCT06177522 Recruiting - Pancreatic Cancer Clinical Trials

Adbelizumab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Start date: December 2023
Phase: Phase 2
Study type: Interventional

Clinical Study on the Safety and Efficacy of the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer

NCT ID: NCT06177301 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Start date: December 1, 2023
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma.

NCT ID: NCT06177041 Recruiting - Clinical trials for Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Start date: December 25, 2023
Phase: Phase 3
Study type: Interventional

Gastric/GEJ adenocarcinoma, which is one of the major leading causes of cancer-related deaths worldwide, is a global challenge to human health. However, standard chemotherapy has limited efficacy in advanced gastric cancer, and there is an urgent need to explore and develop new therapeutic targets and combination therapy modalities. The main purpose of this study is to explore the efficacy of M108 monoclonal antibody plus capecitabine and oxaliplatin (CAPOX) versus placebo plus CAPOX as first-line treatment measured by progression free survival (PFS). This study will also evaluate safety, tolerability, pharmacokinetics and the immunogenicity profile of M108 monoclonal antibody, as well as its effects on quality of life.

NCT ID: NCT06177015 Recruiting - Clinical trials for Metastatic Prostate Cancer

Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

Start date: December 11, 2023
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of intermittent use of darolutamide compared to long-term use in combination with ADT and docetaxel in the treatment of mHSPC patients.

NCT ID: NCT06176911 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: December 5, 2023
Phase: Phase 2
Study type: Interventional

To compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse ITP